ImpediMed Limited (ASX:IPD) Chair Christine Emmanuel-Donnelly delivered her address to the company's 2026 Annual General Meeting on 18 November 2026, disclosing a 15% revenue increase for the year, US reimbursement coverage expansion to 95%, and the completion of a $15.2 million capital raising through a placement and Share Purchase Plan.

Key Points

  • Revenue increased by 15%, or 20% in constant currency, during the year
  • US reimbursement coverage expanded to 95%
  • Initiatives implemented to deliver approximately $5 million in annualised cost savings
  • Capital raising of $15.2 million completed in May via placement and Share Purchase Plan
  • Erik Anderson appointed as Non-Executive Director in early 2026 and subsequently appointed Chief Executive Officer following the departure of Dr Parmjot Bains

Revenue Growth and Cost Savings

According to the Chair's address, ImpediMed recorded revenue growth of 15% during the year, or 20% on a constant currency basis. US reimbursement coverage expanded to 95% over the same period. The company also implemented initiatives designed to deliver approximately $5 million in annualised cost savings, with the filing stating that benefits from these initiatives were already emerging in the company's financial results. No Transformation Incentive payment was made to staff during the year because the applicable performance hurdles were not achieved.

Capital Raising and Board Changes

The company completed a capital raising of $15.2 million in May through a placement and Share Purchase Plan. The Chair described the period as particularly challenging for healthcare and small-cap businesses. Separately, the Board appointed Erik Anderson as a Non-Executive Director in early 2026. The filing states Anderson brought more than 20 years of commercial leadership experience in the US medical device sector, including a most recent role as Division President of the Breast and Skeletal Health business at Hologic. Following the departure of Dr Parmjot Bains, Anderson was subsequently appointed Chief Executive Officer.

Remuneration Report and CEO Incentive Resolution

The Chair noted that the Remuneration Report relates to remuneration outcomes for the previous financial year and does not include proposed incentive arrangements for the current CEO, which are the subject of a separate resolution at the meeting. The filing states the Board reduced cash remuneration during the year and maintained alignment with shareholders through equity participation. With respect to Resolution 6, the filing states the Board believes the proposed long-term incentive award for Erik Anderson appropriately aligns executive reward with shareholder outcomes, requiring the achievement of performance hurdles before value can be realised.